ClinicalTrials.gg
CompletedNCT04212169Updated Sep 28, 2023Results posted

Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis

A Phase 2 interventional study of MEDI3506 and Placebo in Atopic Dermatitis, sponsored by AstraZeneca. Completed at 38 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
214th of 544
148 · median 96
Started
2019
with 57 others
Phase 2
202 of 639
18 open now
Registered
351st of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 214th largest by enrollment of the 544 interventional ones that give a count, is one of 58 that started in 2019, is one of 202 in phase 2, and was the 351st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.

Read the detailed description

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.

Each participant will be assigned randomly to a treatment arm, which could be different strengths of the active treatment or a placebo which does not contain active treatment. Both Participants and investigators will be masked to the treatment assignment.

Approximately 152 participants will take part in this study. There is a 4 weeks screening period to determine eligibility. After eligibility is confirmed, participants will receive investigational drug or placebo during the 16 weeks treatment period. This is then followed by an 8-week follow-up period.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • MEDI3506
  • Safety
  • Efficacy
  • Atopic Dermatitis
  • Eczema
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 65 years inclusive at the time of consent.
  • between 19.0 and 40.0 kg/m2 inclusive.
  • Documented history of chronic AD, for at least 1 year prior to screening Visit 1.
  • Meets at minimum 1 of the criteria, as follows:

    • History of inadequate response to topical medications for AD
    • Subject intolerance to treatment with topical medications for AD, or
    • Topical medications are otherwise medically inadvisable
  • AD that affects ≥ 10% of the body surface area (BSA).
  • An EASI score of ≥ 12 at Visit 1 and ≥ 16 at Visit 3 (Day 1).
  • An IGA score of ≥ 3.

Exclusion criteria

Exclusion Criteria:

  • Any active medical or psychiatric condition, or other reason, that would interfere with evaluation of the product or interpretation of subject safety or study results.
  • Any other abnormal findings from physical examination (including vital signs and [ECG]) or from safety laboratory analysis.
  • Active dermatologic conditions that might confound the diagnosis of AD or would interfere with the assessment of the skin.
  • Known active allergic or irritant contact dermatitis.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    MEDI3506 at dose level 1

    Participant will receive multiple doses of MEDI3506 at dose level 1.

    Drug: MEDI3506

  • Experimental
    MEDI3506 at dose level 2

    Participant will receive multiple doses of MEDI3506 at dose level 2.

    Drug: MEDI3506

  • Experimental
    MEDI3506 at dose level 3

    Participant will receive multiple doses of MEDI3506 at dose level 3.

    Drug: MEDI3506

  • Placebo comparator
    Placebo

    Participant will receive multiple doses of Placebo

    Drug: Placebo

Interventions

  • multiple doses

  • DrugPlacebo

    multiple doses

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 16 in EASI Score

    The EASI evaluates 4 anatomic regions for severity and extent of key disease signs and focuses on the acute and chronic signs of inflammation (ie, erythema, edema, papulation, excoriation, and lichenification). The maximum score is 72, with higher values indicating more severe disease. Analysis was performed using mixed effect model for repeated measures and MCP-mod dose response model.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Subjects Achieving a 90% Reduction From Baseline in EASI Score at Week 16

    To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 90% reduction from baseline in EASI score.

    Time frame: Week 16

  2. Percentage of Subjects Achieving a 75% Reduction From Baseline in EASI Score at Week 16

    To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 75% reduction from baseline in EASI score.

    Time frame: Week 16

  3. Percentage of Subjects Achieving a 50% Reduction From Baseline in EASI Score at Week 16

    To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 50% reduction from baseline in EASI score.

    Time frame: Week 16

  4. Percentage of Subjects Achieving an IGA of 0 (Clear) or 1 (Almost Clear) With at Least a 2 Grade Reduction From Baseline Score at Week 16

    The IGA allows investigators to assess overall AD disease severity at 1 given time point and consists of a 5-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, and 4 = severe disease).

    Time frame: Week 16

  5. Percentage of Subjects Achieving a Reduction of ≥ 3 From Baseline to Week 16 in Weekly Mean of Daily Peak Pruritus NRS

    Peak pruritus (ie, worst itch experienced in the previous 24 hours) assessed using an Numerical Rating Scale (NRS; 0 to 10) with 0 = no itch and 10 = worst imaginable itch. The daily assessments were summarised as a weekly mean.

    Time frame: Week 16

  6. Change From Baseline to Week 16 in Weekly Mean of Daily Peak Pruritus NRS

    Peak pruritus (ie, worst itch experienced in the previous 24 hours) assessed using an Numerical Rating Scale (NRS; 0 to 10) with 0 = no itch and 10 = worst imaginable itch. The daily assessments were summarised as a weekly mean.

    Time frame: Week 16

  7. Change From Baseline to Week 16 in Weekly Mean of Daily Peak Skin Pain NRS

    Skin pain (ie, worst skin pain experienced in the previous 24 hours) assessed using an NRS (0 to 10) with 0 = no pain and 10 = worst imaginable pain. The daily assessments were summarised as a weekly mean.

    Time frame: Week 16

  8. SCORAD: Percent Change From Baseline to Week 16

    SCORAD is a clinical tool for assessing the severity of AD that evaluates the extent and intensity of AD lesions, in addition to subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.

    Time frame: Week 16

  9. Change From Baseline to Week 16 in Percentage Body Surface Area (BSA) Affected by AD

    Change in percentage of body surface area (BSA) affected by AD from baseline at week 16.

    Time frame: Week 16

  10. Change From Baseline to Week 16 in DLQI

    The Dermatology Life Quality Index (DLQI) is a 10-item, patient- completed, health-related quality of life assessment of dermatology conditions with a recall period of 1 week. Each item is scored on a 4-point Likert scale with 0 = not at all ⁄not relevant, 1 = a little, 2 = a lot, and 3 = very much. The score from each item is summed, and the maximum total score is 30 while the minimum score is 0. Higher score means highest (adverse) effect on participant's life.

    Time frame: Week 16

  11. Patient Description of Atopic Dermatitis or Eczema From Patient Global Impression of Severity at Week 16

    The Patient Global Impression of Severity (PGI-S) is a tool that allows patients to rate the severity of a condition over the past 7 days with response options of "No symptoms", "Very mild", "Mild", "Moderate", "Severe" and "Very severe".

    Time frame: Week 16

  12. Change From Baseline to Week 16 in POEM

    The Patient-Oriented Eczema Measure (POEM) is a 7-item questionnaire for assessing disease symptoms including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping occurring in the past week. Each item is scored on a 5-point scale with 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = every day. The total POEM score is calculated by summing the score of each item resulting in a maximum of 28 and a minimum of 0, with higher values indicating severe disease

    Time frame: Week 16

  13. Change From Baseline to Week 16 in 5-D Itch

    The 5-D Itch Scale is a questionnaire consisting of 5 items used specifically to measure the course of itch by asking for the degree, duration, disability and distribution of the pruritus within the last 2 weeks. The scores from each item are summed, with maximum score of 25 and minimum score of 5. Higher score represent worse outcome

    Time frame: Week 16

  14. Occurrence of Adverse Events

    To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

    Time frame: up to 24 weeks

  15. Oral or Tympanic Temperature Taken During Vital Signs Assessment

    Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

    Time frame: Baseline, week 16 and week 24

  16. Systolic Blood Pressure Taken During Vital Signs Assessment

    Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

    Time frame: Baseline, week 16 and week 24

  17. Heart Rate Taken During Vital Signs Assessment

    Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

    Time frame: Baseline, week 16 and week 24

  18. Respiratory Rate Collected During Vital Signs Assessment

    Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

    Time frame: Baseline, week 16 and week 24

  19. Number of Participants With Abnormal Laboratory Assessments Relative to Normal Ranges for Haematology

    To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

    Time frame: up to 24 weeks

  20. Number of Participants With Abnormal Laboratory Assessments Relative to Normal Ranges for Serum Chemistry

    To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

    Time frame: up to 24 weeks

  21. Number of Participants With Abnormal Laboratory Assessments Relative to Normal Ranges for Urinalysis

    To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

    Time frame: up to 24 weeks

  22. Heart Rate (Beats/Min) Recorded on ECGs

    Collectively with other ECG parameters are used t assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

    Time frame: Baseline, week 16 and week 24

  23. QT (Miliseconds) Recorded on ECGs

    Collectively with other ECG parameters are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

    Time frame: Baseline, week 16 and week 24

  24. Number of Participants With Investigator's Overall ECGs Evaluations, e.g. Normal/Abnormal and Their Clinical Significance

    Collectively with other ECG parameters are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

    Time frame: Week 16 and week 24

  25. Left Ventricular Ejection Fraction Measured by Echocardiogram

    To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

    Time frame: Baseline and week 16

  26. Serum MEDI3506 Concentration Profiles

    To evaluate the PK of MEDI3506 in adult subjects with moderate-to-severe AD.

    Time frame: Week 16 and week 24

  27. Occurence of Anti-drug Antibody During the Treatment and Follow-up Periods

    To evaluate the immunogenicity of MEDI3506 in adult subjects with moderate-to-severe AD.

    Time frame: up to 24 weeks

07

Results

Posted Sep 28, 2023

Participant flow

Participant flow — Overall Study
MilestonePlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Started56191855
Completed42161342
Not completed143513
Withdrew: Adverse event0002
Withdrew: Lost to follow-up1002
Withdrew: Withdrawal by subject10257
Withdrew: Other reason, unspecified3102

Outcome measures

PrimaryPercent Change From Baseline to Week 16 in EASI Score

The EASI evaluates 4 anatomic regions for severity and extent of key disease signs and focuses on the acute and chronic signs of inflammation (ie, erythema, edema, papulation, excoriation, and lichenification). The maximum score is 72, with higher values indicating more severe disease. Analysis was performed using mixed effect model for repeated measures and MCP-mod dose response model.

Time frame:
Week 16
Reported as:
Least squares mean · Percentage of change from baseline
Percent Change From Baseline to Week 16 in EASI Score
Percentage of change from baselinePlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Percent change from baseline to Week 16 in EASI score analysed using MCP-mod dose response modelNA ± NANA ± NANA ± NANA ± NA
Percent change from baseline to Week 16 in EASI score analysed using a repeated measures mixed model-51.31 ± 5.214-50.03 ± 7.419-45.43 ± 8.402-53.02 ± 4.858
Statistical analysis
  • MEDI3506 Dose 1 · Mixed Models Analysis · p = 0.888 · Mean difference (final values): 1.27 · 90% CI -13.67 to 16.22Differences less than 0 favours MEDI3506
  • MEDI3506 Dose 2 · Mixed Models Analysis · p = 0.549 · Mean difference (final values): 5.87 · 90% CI -10.36 to 22.10Differences less than 0 favours MEDI3506
  • MEDI3506 Dose 3 · Mixed Models Analysis · p = 0.807 · Mean difference (final values): -1.72 · 90% CI -13.38 to 9.95Differences less than 0 favours MEDI3506
SecondaryPercentage of Subjects Achieving a 90% Reduction From Baseline in EASI Score at Week 16

To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 90% reduction from baseline in EASI score.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving a 90% Reduction From Baseline in EASI Score at Week 16
ParticipantsPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Percentage of Subjects Achieving a 90% Reduction From Baseline in EASI Score at Week 160013
SecondaryPercentage of Subjects Achieving a 75% Reduction From Baseline in EASI Score at Week 16

To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 75% reduction from baseline in EASI score.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving a 75% Reduction From Baseline in EASI Score at Week 16
ParticipantsPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Percentage of Subjects Achieving a 75% Reduction From Baseline in EASI Score at Week 1642110
Statistical analysis
  • MEDI3506 Dose 1 · Fisher Exact · p = 0.6396 · Odds ratio (or): 1.53 · 90% CI 0.19 to 9.94Odds ratio greater than 1 favours MEDI3506
  • MEDI3506 Dose 2 · Fisher Exact · p = 0.9999 · Odds ratio (or): 0.76 · 90% CI 0.03 to 6.38Odds ratio greater than 1 favours MEDI3506
  • MEDI3506 Dose 3 · Regression, Logistic · p = 0.0935 · Odds ratio (or): 2.89 · 90% CI 0.91 to 10.49Odds ratio greater than 1 favours MEDI3506
SecondaryPercentage of Subjects Achieving a 50% Reduction From Baseline in EASI Score at Week 16

To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 50% reduction from baseline in EASI score.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving a 50% Reduction From Baseline in EASI Score at Week 16
ParticipantsPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Percentage of Subjects Achieving a 50% Reduction From Baseline in EASI Score at Week 16125516
SecondaryPercentage of Subjects Achieving an IGA of 0 (Clear) or 1 (Almost Clear) With at Least a 2 Grade Reduction From Baseline Score at Week 16

The IGA allows investigators to assess overall AD disease severity at 1 given time point and consists of a 5-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, and 4 = severe disease).

Time frame:
Week 16
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving an IGA of 0 (Clear) or 1 (Almost Clear) With at Least a 2 Grade Reduction From Baseline Score at Week 16
ParticipantsPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
IGA response rate at Week 161105
IGA response rate at Week 16 using MCP-Mod dose-response analysisNANANANA
Statistical analysis
  • MEDI3506 Dose 1 · Fisher Exact · p = 0.4450 · Odds ratio (or): 3.06 · 90% CI 0.08 to 119.65Odds ratio greater than one favour MEDI3506
  • MEDI3506 Dose 2 · Fisher Exact · p = 0.9999 · Odds ratio (or): 0 · 90% CI 0.0 to 28.0Odds ratio greater than 1 favours MEDI3506
  • MEDI3506 Dose 3 · Fisher Exact · p = 0.1132 · Odds ratio (or): 5.50 · 90% CI 0.75 to 130.35Odds ratio greater than 1 favours MEDI3506
SecondaryPercentage of Subjects Achieving a Reduction of ≥ 3 From Baseline to Week 16 in Weekly Mean of Daily Peak Pruritus NRS

Peak pruritus (ie, worst itch experienced in the previous 24 hours) assessed using an Numerical Rating Scale (NRS; 0 to 10) with 0 = no itch and 10 = worst imaginable itch. The daily assessments were summarised as a weekly mean.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving a Reduction of ≥ 3 From Baseline to Week 16 in Weekly Mean of Daily Peak Pruritus NRS
ParticipantsPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Percentage of Subjects Achieving a Reduction of ≥ 3 From Baseline to Week 16 in Weekly Mean of Daily Peak Pruritus NRS93312
SecondaryChange From Baseline to Week 16 in Weekly Mean of Daily Peak Pruritus NRS

Peak pruritus (ie, worst itch experienced in the previous 24 hours) assessed using an Numerical Rating Scale (NRS; 0 to 10) with 0 = no itch and 10 = worst imaginable itch. The daily assessments were summarised as a weekly mean.

Time frame:
Week 16
Reported as:
Mean · Scores on a scale
Change From Baseline to Week 16 in Weekly Mean of Daily Peak Pruritus NRS
Scores on a scalePlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Change From Baseline to Week 16 in Weekly Mean of Daily Peak Pruritus NRS-1.41 ± 0.356-1.06 ± 0.519-2.01 ± 0.595-2.24 ± 0.348
SecondaryChange From Baseline to Week 16 in Weekly Mean of Daily Peak Skin Pain NRS

Skin pain (ie, worst skin pain experienced in the previous 24 hours) assessed using an NRS (0 to 10) with 0 = no pain and 10 = worst imaginable pain. The daily assessments were summarised as a weekly mean.

Time frame:
Week 16
Reported as:
Mean · Scores on a scale
Change From Baseline to Week 16 in Weekly Mean of Daily Peak Skin Pain NRS
Scores on a scalePlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Change From Baseline to Week 16 in Weekly Mean of Daily Peak Skin Pain NRS-1.44 ± 2.39-1.66 ± 2.62-1.52 ± 1.61-1.63 ± 2.30
SecondarySCORAD: Percent Change From Baseline to Week 16

SCORAD is a clinical tool for assessing the severity of AD that evaluates the extent and intensity of AD lesions, in addition to subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.

Time frame:
Week 16
Reported as:
Mean · Percentage of change from baseline
SCORAD: Percent Change From Baseline to Week 16
Percentage of change from baselinePlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
SCORAD: Percent Change From Baseline to Week 16-31.79 ± 25.09-29.88 ± 23.14-36.22 ± 25.34-39.42 ± 25.44
SecondaryChange From Baseline to Week 16 in Percentage Body Surface Area (BSA) Affected by AD

Change in percentage of body surface area (BSA) affected by AD from baseline at week 16.

Time frame:
Week 16
Reported as:
Mean · Percentage of body surface area
Change From Baseline to Week 16 in Percentage Body Surface Area (BSA) Affected by AD
Percentage of body surface areaPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Change From Baseline to Week 16 in Percentage Body Surface Area (BSA) Affected by AD-17.81 ± 17.09-11.07 ± 10.92-9.46 ± 13.23-23.13 ± 19.35
SecondaryChange From Baseline to Week 16 in DLQI

The Dermatology Life Quality Index (DLQI) is a 10-item, patient- completed, health-related quality of life assessment of dermatology conditions with a recall period of 1 week. Each item is scored on a 4-point Likert scale with 0 = not at all ⁄not relevant, 1 = a little, 2 = a lot, and 3 = very much. The score from each item is summed, and the maximum total score is 30 while the minimum score is 0. Higher score means highest (adverse) effect on participant's life.

Time frame:
Week 16
Reported as:
Mean · Scores on scale
Change From Baseline to Week 16 in DLQI
Scores on scalePlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Change From Baseline to Week 16 in DLQI-2.9 ± 5.3-2.1 ± 6.5-2.4 ± 4.9-2.7 ± 4.9
SecondaryPatient Description of Atopic Dermatitis or Eczema From Patient Global Impression of Severity at Week 16

The Patient Global Impression of Severity (PGI-S) is a tool that allows patients to rate the severity of a condition over the past 7 days with response options of "No symptoms", "Very mild", "Mild", "Moderate", "Severe" and "Very severe".

Time frame:
Week 16
Reported as:
Count of participants · Participants
Patient Description of Atopic Dermatitis or Eczema From Patient Global Impression of Severity at Week 16
ParticipantsPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
No symptoms1011
Very mild50510
Mild9428
Moderate115114
Severe11426
Very severe1211
Missing data184615
SecondaryChange From Baseline to Week 16 in POEM

The Patient-Oriented Eczema Measure (POEM) is a 7-item questionnaire for assessing disease symptoms including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping occurring in the past week. Each item is scored on a 5-point scale with 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = every day. The total POEM score is calculated by summing the score of each item resulting in a maximum of 28 and a minimum of 0, with higher values indicating severe disease

Time frame:
Week 16
Reported as:
Mean · Scores on scale
Change From Baseline to Week 16 in POEM
Scores on scalePlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Change From Baseline to Week 16 in POEM-5.4 ± 7.9-2.5 ± 4.8-3.7 ± 8.7-6.3 ± 6.9
SecondaryChange From Baseline to Week 16 in 5-D Itch

The 5-D Itch Scale is a questionnaire consisting of 5 items used specifically to measure the course of itch by asking for the degree, duration, disability and distribution of the pruritus within the last 2 weeks. The scores from each item are summed, with maximum score of 25 and minimum score of 5. Higher score represent worse outcome

Time frame:
Week 16
Reported as:
Mean · Scores on scale
Change From Baseline to Week 16 in 5-D Itch
Scores on scalePlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Change From Baseline to Week 16 in 5-D Itch-3.0 ± 4.9-3.0 ± 2.6-3.8 ± 3.4-4.0 ± 5.1
SecondaryOccurrence of Adverse Events

To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

Time frame:
up to 24 weeks
Reported as:
Count of participants · Participants
Occurrence of Adverse Events
ParticipantsPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
At least one adverse event3791432
At least one investigational product related event7378
At least one event of ≥ grade 3 severity7225
At least one serious event2021
At least one investigational product related serious event0010
SecondaryOral or Tympanic Temperature Taken During Vital Signs Assessment

Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

Time frame:
Baseline, week 16 and week 24
Reported as:
Mean · degrees C
Oral or Tympanic Temperature Taken During Vital Signs Assessment
degrees CPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Baseline36.46 ± 0.3536.43 ± 0.5236.41 ± 0.4336.52 ± 0.39
Week 1636.49 ± 0.3636.71 ± 0.4136.50 ± 0.3236.47 ± 0.39
Week 2436.44 ± 0.4336.63 ± 0.5036.55 ± 0.4236.51 ± 0.37
SecondarySystolic Blood Pressure Taken During Vital Signs Assessment

Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

Time frame:
Baseline, week 16 and week 24
Reported as:
Mean · mmHg
Systolic Blood Pressure Taken During Vital Signs Assessment
mmHgPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Baseline117.7 ± 12.9119.3 ± 9.2123.8 ± 9.9121.5 ± 12.5
Week 16117.8 ± 9.6117.3 ± 7.2120.7 ± 13.6119.8 ± 10.6
Week 24118.9 ± 11.1117.6 ± 11.4120.1 ± 15.1120.6 ± 12.1
SecondaryHeart Rate Taken During Vital Signs Assessment

Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

Time frame:
Baseline, week 16 and week 24
Reported as:
Mean · Pulse Rate (beats/min)
Heart Rate Taken During Vital Signs Assessment
Pulse Rate (beats/min)PlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Baseline68.1 ± 9.866.6 ± 8.771.3 ± 9.368.2 ± 11.1
Week 1669.4 ± 10.166.9 ± 10.665.9 ± 8.666.4 ± 11.0
Week 2472.0 ± 13.567.0 ± 10.474.1 ± 8.767.6 ± 10.1
SecondaryRespiratory Rate Collected During Vital Signs Assessment

Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

Time frame:
Baseline, week 16 and week 24
Reported as:
Mean · breaths/min
Respiratory Rate Collected During Vital Signs Assessment
breaths/minPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Baseline15.4 ± 2.216.0 ± 1.516.2 ± 1.815.5 ± 1.8
Week 1616.0 ± 2.315.7 ± 1.816.3 ± 1.915.9 ± 1.4
Week 2415.8 ± 2.416.1 ± 1.517.1 ± 2.415.6 ± 1.6
SecondaryNumber of Participants With Abnormal Laboratory Assessments Relative to Normal Ranges for Haematology

To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

Time frame:
up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Laboratory Assessments Relative to Normal Ranges for Haematology
ParticipantsPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Basophils — At Least One Post-Baseline Value Below LLN0000
Basophils — At Least One Post-Baseline Value Above ULN3000
Basophils — Values within normal range53191855
Eosinophils — At Least One Post-Baseline Value Below LLN0000
Eosinophils — At Least One Post-Baseline Value Above ULN224514
Eosinophils — Values within normal range34151341
Hematocrit — At Least One Post-Baseline Value Below LLN4327
Hematocrit — At Least One Post-Baseline Value Above ULN0010
Hematocrit — Values within normal range52161548
Haemoglobin — At Least One Post-Baseline Value Below LLN5138
Haemoglobin — At Least One Post-Baseline Value Above ULN0010
Haemoglobin — Values within normal range51181447
Lymphocytes — At Least One Post-Baseline Value Below LLN60310
Lymphocytes — At Least One Post-Baseline Value Above ULN0000
Lymphocytes — Values within normal range50191545
Monocytes — At Least One Post-Baseline Value Below LLN1013
Monocytes — At Least One Post-Baseline Value Above ULN2023
Monocytes — Values within normal range53191549
Platelet count — At Least One Post-Baseline Value Below LLN1100
Platelet count — At Least One Post-Baseline Value Above ULN3025
Platelet count — Values within normal range52181650
Erythrocytes — At Least One Post-Baseline Value Below LLN103417
Erythrocytes — At Least One Post-Baseline Value Above ULN0000
Erythrocytes — Values within normal range46161438
White blood cell count — At Least One Post-Baseline Value Below LLN7126
White blood cell count — At Least One Post-Baseline Value Above ULN5202
White blood cell count — Values within normal range44161647
SecondaryNumber of Participants With Abnormal Laboratory Assessments Relative to Normal Ranges for Serum Chemistry

To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

Time frame:
up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Laboratory Assessments Relative to Normal Ranges for Serum Chemistry
ParticipantsPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Albumin — At Least One Post-Baseline Value Below LLN0000
Albumin — At Least One Post-Baseline Value Above ULN215615
Albumin — Values within normal range35141240
Alkaline Phosphatase — At Least One Post-Baseline Value Below LLN3002
Alkaline Phosphatase — At Least One Post-Baseline Value Above ULN3224
Alkaline Phosphatase — Values within normal range50171649
Alanine Aminotransferase — At Least One Post-Baseline Value Below LLN0000
Alanine Aminotransferase — At Least One Post-Baseline Value Above ULN7445
Alanine Aminotransferase — Values within normal range49151450
Aspartate Aminotransferase — At Least One Post-Baseline Value Below LLN0000
Aspartate Aminotransferase — At Least One Post-Baseline Value Above ULN6338
Aspartate Aminotransferase — Values within normal range50161547
Bilirubin — At Least One Post-Baseline Value Below LLN0000
Bilirubin — At Least One Post-Baseline Value Above ULN3011
Bilirubin — Values within normal range53191754
Urea Nitrogen — At Least One Post-Baseline Value Below LLN0000
Urea Nitrogen — At Least One Post-Baseline Value Above ULN0002
Urea Nitrogen — Values within normal range56191853
Creatinine — At Least One Post-Baseline Value Below LLN0000
Creatinine — At Least One Post-Baseline Value Above ULN0013
Creatinine — Values within normal range56191752
Gamma Glutamyl Transferase — At Least One Post-Baseline Value Below LLN4205
Gamma Glutamyl Transferase — At Least One Post-Baseline Value Above ULN2321
Gamma Glutamyl Transferase — Values within normal range50141649
Potassium — At Least One Post-Baseline Value Below LLN1101
Potassium — At Least One Post-Baseline Value Above ULN1011
Potassium — Values within normal range54181753
Sodium — At Least One Post-Baseline Value Below LLN0000
Sodium — At Least One Post-Baseline Value Above ULN2002
Sodium — Values within normal range54191853
SecondaryNumber of Participants With Abnormal Laboratory Assessments Relative to Normal Ranges for Urinalysis

To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

Time frame:
up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Laboratory Assessments Relative to Normal Ranges for Urinalysis
ParticipantsPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
pH — At Least One Post-Baseline Value Below LLN0000
pH — At Least One Post-Baseline Value Above ULN0001
pH — Values within normal range56191854
Erythrocytes — At Least One Post-Baseline Value Below LLN0000
Erythrocytes — At Least One Post-Baseline Value Above ULN8216
Erythrocytes — Values within normal range48171749
Specific gravity — At Least One Post-Baseline Value Below LLN0000
Specific gravity — At Least One Post-Baseline Value Above ULN4037
Specific gravity — Values within normal range52191548
Leukocytes — At Least One Post-Baseline Value Below LLN0000
Leukocytes — At Least One Post-Baseline Value Above ULN4215
Leukocytes — Values within normal range52171750
SecondaryHeart Rate (Beats/Min) Recorded on ECGs

Collectively with other ECG parameters are used t assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

Time frame:
Baseline, week 16 and week 24
Reported as:
Mean · beats per minute
Heart Rate (Beats/Min) Recorded on ECGs
beats per minutePlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Baseline67.59 ± 9.8265.61 ± 6.8772.63 ± 9.8265.18 ± 9.43
Week 1666.02 ± 9.9763.80 ± 8.5665.42 ± 9.0863.05 ± 10.61
Week 2468.17 ± 13.9463.88 ± 10.4172.46 ± 9.1264.58 ± 9.43
SecondaryQT (Miliseconds) Recorded on ECGs

Collectively with other ECG parameters are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

Time frame:
Baseline, week 16 and week 24
Reported as:
Mean · milliseconds
QT (Miliseconds) Recorded on ECGs
millisecondsPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Baseline385.43 ± 27.75390.67 ± 20.57380.04 ± 26.38390.27 ± 22.69
Week 16387.05 ± 26.14390.40 ± 24.24395.75 ± 20.36391.95 ± 29.22
Week 24385.88 ± 34.31398.69 ± 28.52383.15 ± 19.05393.40 ± 26.54
SecondaryNumber of Participants With Investigator's Overall ECGs Evaluations, e.g. Normal/Abnormal and Their Clinical Significance

Collectively with other ECG parameters are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

Time frame:
Week 16 and week 24
Reported as:
Count of participants · Participants
Number of Participants With Investigator's Overall ECGs Evaluations, e.g. Normal/Abnormal and Their Clinical Significance
ParticipantsPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Week 16 — Abnormal ECG: Clinically significant0000
Week 16 — Abnormal ECG: Not Clinically significant32210
Week 16 — Normal ECG38131032
Week 16 — Missing154613
Week 24 — Abnormal ECG: Clinically significant0000
Week 24 — Abnormal ECG: Not Clinically significant44211
Week 24 — Normal ECG38121129
Week 24 — Missing143515
SecondaryLeft Ventricular Ejection Fraction Measured by Echocardiogram

To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

Time frame:
Baseline and week 16
Reported as:
Mean · % LVEF
Left Ventricular Ejection Fraction Measured by Echocardiogram
% LVEFPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Baseline64.3 ± 6.364.7 ± 6.262.8 ± 5.263.6 ± 4.7
Week 1664.3 ± 5.963.0 ± 4.461.0 ± 3.665.2 ± 5.1
SecondarySerum MEDI3506 Concentration Profiles

To evaluate the PK of MEDI3506 in adult subjects with moderate-to-severe AD.

Time frame:
Week 16 and week 24
Reported as:
Geometric mean · μg/mL
Serum MEDI3506 Concentration Profiles
μg/mLMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Week 160.377 ± 2422.158 ± 1935.979 ± 118
Week 240.018 ± 1840.118 ± 2980.188 ± 234
SecondaryOccurence of Anti-drug Antibody During the Treatment and Follow-up Periods

To evaluate the immunogenicity of MEDI3506 in adult subjects with moderate-to-severe AD.

Time frame:
up to 24 weeks
Reported as:
Count of participants · Participants
Occurence of Anti-drug Antibody During the Treatment and Follow-up Periods
ParticipantsPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Baseline ADA result1000
Post-baseline ADA result1102

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/56 (0%)2/56 (3.6%)29/56 (51.8%)
MEDI3506 Dose 10/19 (0%)0/19 (0%)11/19 (57.9%)
MEDI3506 Dose 20/18 (0%)2/18 (11.1%)14/18 (77.8%)
MEDI3506 Dose 30/55 (0%)1/55 (1.8%)25/55 (45.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Covid-19 pneumoniaInfections and infestations0/560/191/180/55
Venous thrombosis limbVascular disorders0/560/191/180/55
Medical device removalSurgical and medical procedures0/560/190/181/55
Food allergyImmune system disorders1/560/190/180/55
Dermatitis exfoliative generalisedSkin and subcutaneous tissue disorders1/560/190/180/55
Most frequent other events
Showing 10 of 42
Most frequent other events
EventPlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3
Dermatitis atopicSkin and subcutaneous tissue disorders12/562/190/1814/55
Covid-19Infections and infestations7/560/190/182/55
NasopharyngitisInfections and infestations1/561/192/183/55
Pain in extremityMusculoskeletal and connective tissue disorders1/560/192/180/55
EczemaSkin and subcutaneous tissue disorders3/560/192/182/55
PruritusSkin and subcutaneous tissue disorders3/561/192/181/55
Injection site reactionGeneral disorders0/560/191/184/55
Injection site bruisingGeneral disorders0/560/191/181/55
Injection site swellingGeneral disorders1/560/191/180/55
BronchitisInfections and infestations0/560/191/180/55

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3Total
Mean32.3 ± 11.428.7 ± 8.937.9 ± 14.334.6 ± 11.833.4 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3Total
Female27872567
Male2911113081
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3Total
AMERICAN INDIAN OR ALASKA NATIVE00000
ASIAN853622
BLACK OR AFRICAN AMERICAN11226
MULTIPLE CATEGORIES CHECKED10102
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER00000
OTHER00123
WHITE46131145115
Region of Enrollment
Region of Enrollment(Participants)PlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3Total
USA603716
Australia00112
Germany513211
Spain700512
United Kingdom341393591
Poland452516
Eczema Area and Severity Index (EASI) score
Eczema Area and Severity Index (EASI) score(Scores on a scale)PlaceboMEDI3506 Dose 1MEDI3506 Dose 2MEDI3506 Dose 3Total
Mean28.81 ± 8.9028.94 ± 11.6628.36 ± 11.8732.30 ± 10.8630.07 ± 10.43
08

Study locations

38 sites
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    Miami, Florida 33180, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Baton Rouge, Louisiana 70808, United States
  • Research Site
    Charlotte, North Carolina 28277, United States
  • Research Site
    Tulsa, Oklahoma 74136, United States
  • Research Site
    Providence, Rhode Island 02903, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research Site
    San Antonio, Texas 78213, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    Carlton, 3053, Australia
  • Research Site
    East Melbourne, 3002, Australia
  • Research Site
    Fremantle, 6160, Australia
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Mahlow, 15831, Germany
  • Research Site
    Bialystok, 15-453, Poland
  • Research Site
    Kielce, 25-355, Poland
  • Research Site
    Poznan, 60-681, Poland
  • Research Site
    Skierniewice, 96-100, Poland
  • Research Site
    Wroclaw, 50-566, Poland
  • Research Site
    Łódź, 90-436, Poland
  • Research Site
    Alcobendas, 28100, Spain
  • Research Site
    Leganés, 28915, Spain
  • Research Site
    Sevilla, 41003, Spain
  • Research Site
    Corby, NN18 9EZ, United Kingdom
  • Research Site
    High Wycombe, HP11 2QW, United Kingdom
  • Research Site
    Kenilworth, CV8 1JD, United Kingdom
  • Research Site
    Northwood, HA6 2RN, United Kingdom
  • Research Site
    Romford, RM1 3PJ, United Kingdom
  • Research Site
    Shipley, BD18 3SA, United Kingdom
  • Research Site
    Sidcup, DA14 6LT, United Kingdom
  • Research Site
    Wokingham, RG40 1XS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Jul 2022, 31 months.

Results were first posted in Sep 2023, 1 year 2 months after primary completion.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 31 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2019
First posted
Dec 26, 2019
StartActual
Dec 9, 2019
Primary completionActual
Jul 21, 2022
CompletionActual
Sep 20, 2022
Results first posted
Sep 28, 2023
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04212169
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 26, 2019
Start date
Dec 9, 2019
Primary completion
Jul 21, 2022
Completion
Sep 20, 2022
Results posted
Sep 28, 2023
Last update
Sep 28, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tozorakimab

Start the discussion